Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with CD19-positive B cell Non-Hodgkin Lymphoma (a type of blood cancer), Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma, confirmed by laboratory testing, and who have already received at least 2 previous treatments.
• People enrolling in the Phase Ib part of the trial must have Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma specifically.
• People who are reasonably active and able to care for themselves (rated 0 or 1 on a standard medical activity scale).
• People aged 18 or older at the time of signing consent.
• People whose doctors estimate they have a life expectancy of more than 4 months.
• People whose heart, lungs, liver, kidneys, bone marrow, and other key organs are functioning well enough to meet the trial's health requirements.
• People whose treating doctor considers their disease to be incurable and who may be a suitable candidate for the trial treatment within the next 3 months.
• People who are able to give proper informed consent in line with local and regulatory requirements.

Who may not be able to join:

• People with serious ongoing illnesses or medical conditions that could interfere with taking part in the trial.
• People with an active autoimmune disease (where the immune system attacks the body), or who have had one within the past 2 years.
• People with a history of a condition where the immune system does not work properly from birth or early life (primary immunodeficiency).
• People who have had an organ transplant and need to take medications to prevent rejection.
• People with a known allergy or sensitivity to any ingredient in the trial drug.
• People who have cancer that has spread to the brain or spinal cord and has not yet been treated.
• People who have had another serious cancer within the past 2 years (some non-invasive cancers may be exceptions — confirm with trial site).
• People who have taken immune-suppressing medications within 14 days before the cell collection procedure (apheresis).
• People with untreated active tuberculosis.
• People who are HIV positive.
• People with an active HTLV (a virus affecting white blood cells) or active syphilis infection.
• People with active Hepatitis B or active Hepatitis C (people with a negative blood test showing no detectable virus may still be considered — confirm with trial site).
• People who are pregnant or breastfeeding.
• People who have previously received a bone marrow or stem cell transplant from another person (allogeneic transplant).
• People who have previously received any treatment that specifically targets CD19 (the same marker this trial targets).
• People who have received a live vaccine within 28 days before the cell collection procedure.
• People whose doctor believes, for any other reason, that participation would not be appropriate or safe.

Important: Always verify eligibility with the trial site directly before applying.